Open Payments

Boston Medical Center

Type
Teaching hospital
Where
Boston, MA
Medicare CCN
220031
Received
$6,773,688 in 483 records, 2025 ($924,243 general, $5,849,444 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment73$924,243
2025Research payment410$5,849,444

By company

CompanyRecordsAmountYears
E.R. Squibb & Sons, L.L.C.13$1,101,1192025
Takeda Pharmaceuticals U.S.A., Inc.21$1,071,3692025
Merck Sharp & Dohme LLC14$841,6932025
Janssen Research & Development, LLC44$363,8782025
PFIZER INC.26$351,9512025
Genentech, Inc.25$334,8572025
VERTEX PHARMACEUTICALS INCORPORATED2$297,0352025
Zevra Therapeutics Inc3$214,0592025
Theratechnologies Inc.4$191,9322025
Madrigal Pharmaceuticals30$188,7782025
ABBVIE INC.14$186,3352025
Indivior Inc.21$174,9832025
Alnylam Pharmaceuticals Inc.1$167,0002025
Eli Lilly and Company5$137,7232025
Lexicon Pharmaceuticals, Inc.2$132,5582025
Gilead Sciences, Inc.14$128,0442025
Sequel Med Tech, LLC112$125,6082025
Abbott Laboratories16$97,1752025
Deciphera Pharmaceuticals Inc.3$88,9032025
UCB SA3$71,7712025
Alexion Pharmaceuticals, Inc.6$70,9872025
Humacyte Global, Inc.7$46,2882025
F. Hoffmann-La Roche AG7$38,6962025
Novo Nordisk AS15$32,0852025
Agios Pharmaceuticals, Inc.8$31,1672025
Eidos Therapeutics, Inc.2$23,1252025
Bard Peripheral Vascular, Inc.3$22,0182025
Davol Inc.1$20,9302025
Medtronic, Inc.1$20,8802025
Coherus Oncology, Inc.2$20,0002025
GLOBAL BLOOD THERAPEUTICS, INC.5$19,9412025
Novartis Pharmaceuticals Corporation2$19,3612025
KARL STORZ Endoscopy-America15$19,0612025
GE HEALTHCARE5$16,5862025
Insulet Corporation1$15,1842025
KLS-Martin L.P.4$15,0002025
Biosense Webster, Inc.1$15,0002025
Stryker Corporation7$11,5412025
Regeneron Pharmaceuticals, Inc.2$11,2252025
BeOne Medicines USA, Inc.1$10,0002025
SANOFI PASTEUR INC.1$7,5002025
Route 92 Medical, Inc.1$6,8772025
Mannkind Corporation1$3,9672025
INSTYLLA, INC.1$2,6002025
Organon Llc2$2,5142025
Haemonetics Corporation1$2,1692025
Fisher Scientific Company L.L.C.1$9462025
National Marrow Donor Program2$8602025
SANOFI US SERVICES INC.1$1502025
WERFEN USA LLC1$1392025

By nature of payment

NatureRecordsAmount
Research payment410$5,849,444
Grant13$446,425
Compensation for services other than consulting, including serving as faculty or as a speaker at a v23$175,843
Charitable Contribution9$167,353
Education16$119,061
Long term medical supply or device loan6$12,859
Debt forgiveness4$1,812
Space rental or facility fees (teaching hospital only)1$748
Food and Beverage1$139

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Merck Sharp & Dohme LLC$292,646Research paymentIn-kind items and servicesGARDASIL 9 Biological, VACCINEAn Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose Vaccination Regimen over 6 months Amon2025
2025-12-31Merck Sharp & Dohme LLC$15,450Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792025
2025-12-31Merck Sharp & Dohme LLC$8,666Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2025
2025-12-31KARL STORZ Endoscopy-America$7,224EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2025
2025-12-31Sequel Med Tech, LLC$7,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Stryker Corporation$3,477Long term medical supply or device loanIn-kind items and servicesCORE Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,477Long term medical supply or device loanIn-kind items and servicesCORE Device, INSTRUMENTS2025
2025-12-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31KARL STORZ Endoscopy-America$2,584EducationIn-kind items and servicesIMAGE 1 Device, T-VIDEOIMAGING2025
2025-12-31Sequel Med Tech, LLC$2,223Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$2,223Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$2,223Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$2,223Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$2,223Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$2,160Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31KARL STORZ Endoscopy-America$2,034EducationIn-kind items and servicesHOPKINS Device, K-LAPAROSCOPY2025
2025-12-31KARL STORZ Endoscopy-America$2,034EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2025
2025-12-31Stryker Corporation$1,860Long term medical supply or device loanIn-kind items and servicesSTRYKER Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$1,860Long term medical supply or device loanIn-kind items and servicesSTRYKER Device, INSTRUMENTS2025
2025-12-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31KARL STORZ Endoscopy-America$877EducationIn-kind items and services2025
2025-12-31KARL STORZ Endoscopy-America$728EducationIn-kind items and servicesn.a. Device, K-LAPAROSCOPY2025
2025-12-31KARL STORZ Endoscopy-America$728EducationIn-kind items and servicesn.a. Device, K-LAPAROSCOPY2025
2025-12-31KARL STORZ Endoscopy-America$728EducationIn-kind items and servicesn.a. Device, K-LAPAROSCOPY2025
2025-12-31KARL STORZ Endoscopy-America$728EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2025
2025-12-31Sequel Med Tech, LLC$666Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$666Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$666Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$666Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$666Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Stryker Corporation$602Debt forgivenessCash or cash equivalent2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31KARL STORZ Endoscopy-America$422EducationIn-kind items and services2025
2025-12-31KARL STORZ Endoscopy-America$282EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2025
2025-12-31KARL STORZ Endoscopy-America$213EducationIn-kind items and servicesCLICKLINE Device, LAPAROSCOPY2025
2025-12-31KARL STORZ Endoscopy-America$185EducationIn-kind items and servicesCLICKLINE Device, LAPAROSCOPY2025
2025-12-31Stryker Corporation$182Debt forgivenessCash or cash equivalent2025
2025-12-31Merck Sharp & Dohme LLC$175Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2025
2025-12-31KARL STORZ Endoscopy-America$154EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31KARL STORZ Endoscopy-America$136EducationIn-kind items and servicesCLICKLINE Device, LAPAROSCOPY2025
2025-12-31Stryker Corporation$81Debt forgivenessCash or cash equivalent2025
2025-12-29PFIZER INC.$50,000Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESSURVEILLANCE OF INVASIVE PNEUMOCOCCAL DISEASES IPD IN MASSACHUSETTS CHILDREN2025
2025-12-22Novo Nordisk AS$8,445Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522025
2025-12-22Merck Sharp & Dohme LLC$8,185Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2025
2025-12-22Janssen Research & Development, LLC$6,723Research paymentCash or cash equivalentA Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm2025
2025-12-22Janssen Research & Development, LLC$4,272Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car2025
2025-12-22Novo Nordisk AS$3,098Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522025
2025-12-22Novo Nordisk AS$1,500Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522025
2025-12-19F. Hoffmann-La Roche AG$20,963Research paymentCash or cash equivalentA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan2025
2025-12-19F. Hoffmann-La Roche AG$4,030Research paymentCash or cash equivalentA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan2025
2025-12-19F. Hoffmann-La Roche AG$3,588Research paymentCash or cash equivalentA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan2025
2025-12-19F. Hoffmann-La Roche AG$3,422Research paymentCash or cash equivalentA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan2025
2025-12-19F. Hoffmann-La Roche AG$2,959Research paymentCash or cash equivalentA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan2025
2025-12-19F. Hoffmann-La Roche AG$2,564Research paymentCash or cash equivalentUC P3: Double-Blind Treat Straight Through2025
2025-12-19Madrigal Pharmaceuticals$195Research paymentCash or cash equivalentREZDIFFRA Drug, LIVER DISEASEA 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET2025
2025-12-18Janssen Research & Development, LLC$4,742Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2025
2025-12-18Organon Llc$14Long term medical supply or device loanIn-kind items and servicesJADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING2025
2025-12-17Medtronic, Inc.$20,880GrantCash or cash equivalent2025
2025-12-15Janssen Research & Development, LLC$5,434Research paymentCash or cash equivalentA Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced 2025
2025-12-12Davol Inc.$20,930Research paymentCash or cash equivalentDVL-HE-0182025
2025-12-12SANOFI PASTEUR INC.$7,500Research paymentCash or cash equivalentPhase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, I2025
2025-12-10Takeda Pharmaceuticals U.S.A., Inc.$292Research paymentCash or cash equivalentSTUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI2025
2025-12-05Janssen Research & Development, LLC$43,692Research paymentCash or cash equivalentA Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm2025
2025-12-04E.R. Squibb & Sons, L.L.C.$39,978Research paymentCash or cash equivalentA Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS2025
2025-12-04Janssen Research & Development, LLC$8,515Research paymentCash or cash equivalentA Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced 2025
2025-12-04Madrigal Pharmaceuticals$5,423Research paymentCash or cash equivalentREZDIFFRA Drug, LIVER DISEASEA 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET2025
2025-12-04ABBVIE INC.$2,437Research paymentCash or cash equivalentA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch2025
2025-12-02Gilead Sciences, Inc.$28,028GrantCash or cash equivalent2025
2025-12-01Humacyte Global, Inc.$9,664Research paymentCash or cash equivalentSymvess Biological, Extremity Arterial InjuryTo Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi2025
2025-12-01Humacyte Global, Inc.$2,491Research paymentCash or cash equivalentSymvess Biological, Extremity Arterial InjuryTo Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi2025
2025-11-30Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$2,223Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$2,223Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$2,223Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$666Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$666Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$666Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-30Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-11-28Janssen Research & Development, LLC$23,400Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS)2025
2025-11-28Janssen Research & Development, LLC$2,460Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS)2025
2025-11-28Janssen Research & Development, LLC$1,950Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS)2025
2025-11-26Eidos Therapeutics, Inc.$19,225Research paymentCash or cash equivalentAttruby Drug, CardiomyopathyA Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis P2025
2025-11-26Eidos Therapeutics, Inc.$3,900Research paymentCash or cash equivalentAttruby Drug, CardiomyopathyA Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis P2025
2025-11-25Genentech, Inc.$7,418Research paymentCash or cash equivalentA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan2025
2025-11-25Genentech, Inc.$3,055Research paymentCash or cash equivalentUC P3: Double-Blind Treat Straight Through2025
2025-11-25Genentech, Inc.$3,042Research paymentCash or cash equivalentUC P3: Double-Blind Treat Straight Through2025
2025-11-25Madrigal Pharmaceuticals$1,903Research paymentCash or cash equivalentREZDIFFRA Drug, LIVER DISEASEA 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET2025
2025-11-25Madrigal Pharmaceuticals$195Research paymentCash or cash equivalentREZDIFFRA Drug, LIVER DISEASEA 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET2025
2025-11-21Janssen Research & Development, LLC$5,027Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2025
2025-11-18Gilead Sciences, Inc.$6,605GrantCash or cash equivalent2025
2025-11-17Merck Sharp & Dohme LLC$28,320Research paymentIn-kind items and servicesGARDASIL 9 Biological, VACCINEAn Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose Vaccination Regimen over 6 months Amon2025
2025-11-17Genentech, Inc.$2,730Research paymentCash or cash equivalentActemra Biological, ImmunologyPh3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL2025
2025-11-14Genentech, Inc.$928Research paymentCash or cash equivalentTecentriq Biological, BioOncologyPhase 2 Study of Autogene Cevumeran in Adjuvant PDAC2025
2025-11-12Takeda Pharmaceuticals U.S.A., Inc.$10,648Research paymentCash or cash equivalentSTUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI2025
2025-11-10Abbott Laboratories$460Research paymentCash or cash equivalentESPRIT Device, VascularNCT04227899--LIFE-BTK Randomized Controlled Trial2025
2025-11-07Genentech, Inc.$18,142Research paymentCash or cash equivalentUC P3: Double-Blind Treat Straight Through2025
2025-11-07Janssen Research & Development, LLC$8,112Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car2025
2025-11-07Genentech, Inc.$4,225Research paymentCash or cash equivalentUC P3: Double-Blind Treat Straight Through2025
2025-11-07Genentech, Inc.$1,950Research paymentCash or cash equivalentUC P3: Double-Blind Treat Straight Through2025
2025-11-07Madrigal Pharmaceuticals$1,903Research paymentCash or cash equivalentREZDIFFRA Drug, LIVER DISEASEA 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET2025
2025-11-06PFIZER INC.$96Research paymentIn-kind items and servicesPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2025
2025-11-06PFIZER INC.$96Research paymentIn-kind items and servicesPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2025
2025-11-05Theratechnologies Inc.$153,725Research paymentCash or cash equivalentTROGARZO Drug, HIVA Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab 2025
2025-11-05Theratechnologies Inc.$35,035Research paymentCash or cash equivalentTROGARZO Drug, HIVA Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab 2025
2025-11-05Indivior Inc.$19,998Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2025
2025-11-05ABBVIE INC.$6,910Research paymentCash or cash equivalentA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch2025
2025-11-05Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2025
2025-11-05KLS-Martin L.P.$3,750GrantCash or cash equivalent2025
2025-11-05Takeda Pharmaceuticals U.S.A., Inc.$195Research paymentCash or cash equivalentSTUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI2025
2025-11-04Abbott Laboratories$1,199Research paymentIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes CareISM2309001A--Janus 12025
2025-10-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$1,175Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31PFIZER INC.$604Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF REVACCINATING PREGNANT PARTICIPANTS DURING 2025
2025-10-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$352Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-10-29Novo Nordisk AS$476Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522025
2025-10-29Madrigal Pharmaceuticals$195Research paymentCash or cash equivalentREZDIFFRA Drug, LIVER DISEASEA 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET2025
2025-10-29Novo Nordisk AS$125Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522025
2025-10-28Abbott Laboratories$1,250Research paymentCash or cash equivalentESPRIT Device, VascularNCT04227899--LIFE-BTK Randomized Controlled Trial2025
2025-10-27Janssen Research & Development, LLC$2,371Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2025
2025-10-25PFIZER INC.$28,260Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2025
2025-10-24Organon Llc$2,500Research paymentCash or cash equivalent8415-0602025
2025-10-24Abbott Laboratories$748Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-10-24Takeda Pharmaceuticals U.S.A., Inc.$585Research paymentCash or cash equivalentTAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirs2025
2025-10-23Janssen Research & Development, LLC$3,603Research paymentCash or cash equivalentA Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced 2025
2025-10-22Abbott Laboratories$80Research paymentCash or cash equivalentESPRIT Device, VascularNCT04227899--LIFE-BTK Randomized Controlled Trial2025
2025-10-20SANOFI US SERVICES INC.$150Charitable ContributionCash or cash equivalent2025
2025-10-17Genentech, Inc.$1,448Research paymentCash or cash equivalentActemra Biological, ImmunologyPh3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL2025
2025-10-17PFIZER INC.$1,040Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2025
2025-10-14BeOne Medicines USA, Inc.$10,000GrantCash or cash equivalentBRUKINSA Drug, Oncology2025
2025-10-09Genentech, Inc.$9,381Research paymentCash or cash equivalentUC P3: Double-Blind Treat Straight Through2025
2025-10-09Humacyte Global, Inc.$7,125Research paymentCash or cash equivalentSymvess Biological, Extremity Arterial InjuryTo Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi2025
2025-10-09Novo Nordisk AS$162Research paymentCash or cash equivalent Drug4202-HEM-3012025

The latest 200 records of 483.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Suffolk CountyBoston city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.

MeasurePlace (city or town)
Boston, MA
County
Suffolk County, MA
State
Massachusetts
Population B01003666,442785,1217,044,056
Population, 2020 census P1675,647797,9367,029,917
Median age B0100233.333.940.0
Under 18 B0100115.1%16.0%19.4%
65 and over B0100113.0%13.3%17.9%
Households B11001283,374327,1672,785,042
Foreign born B0500227.8%29.8%18.0%
Median household income B19013$97,344$95,631$103,960
Median family income B19113$116,436$112,072$131,675
Per capita income B19301$61,698$58,636$57,897
Poverty rate B1700116.6%16.2%10.0%
Unemployment rate B230256.1%6.3%5.2%
Civilian labor force B23025402,354468,6363,911,446
Mean commute (minutes) B0801330.330.929.1
Bachelor's degree or higher B1500354.9%50.6%47.3%
Housing units B25001310,625357,2903,030,406
Owner-occupied B2500335.7%36.5%62.5%
Renters B2500364.3%63.5%37.5%
Median home value B25077$731,700$705,800$562,100
Median gross rent B25064$2,147$2,129$1,762
White, not Hispanic B0300244.1%43.6%66.6%
Black B0300219.3%17.1%6.4%
Hispanic or Latino B0300219.3%23.2%13.3%
Asian B0300210.3%9.2%7.3%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.